SH Lee

机构：Samsung Medical Center, CHA University Bundang Medical Center, Jeju National University Hospital, Dong-A University, Jeju National University, Sungkyunkwan University

发表论文 347 篇 · 总被引 3709 次 · h-index 34

代表论文

• 4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study (2025 · Journal of Thoracic Oncology · 被引 45)
• PT1.03.06 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA (2025 · Journal of Thoracic Oncology · 被引 5)
• 635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC (2024 · Annals of Oncology · 被引 3)
• P3.18.09 SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy (2025 · Journal of Thoracic Oncology · 被引 2)
• 1348MO SKYSCRAPER-09: Phase II, randomised study of tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN) (2025 · Annals of Oncology · 被引 2)
• 629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC) (2024 · Annals of Oncology · 被引 2)